NCT05652686 2025-09-23
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT06698965 2024-11-21
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Shanghai Chest Hospital
Phase 2 Recruiting
NCT06236997 2024-02-01
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT04254471 2020-02-05
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
Haihe Biopharma Co., Ltd.
Phase 2/3 Unknown
NCT00682981 2016-07-21
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00812266 2016-01-26
Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)
Danish Oncological Lung Cancer Group
Phase 3 Terminated
NCT00912392 2014-09-03
Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Phase 2 Completed